Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.
Identifieur interne : 000331 ( Main/Corpus ); précédent : 000330; suivant : 000332Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.
Auteurs : Anne S. Strik ; Geert R. D'Haens ; Mark LöwenbergSource :
- Clinical case reports [ 2050-0904 ] ; 2019.
Abstract
Available data on switching from originator infliximab to CT-P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side effects might occur, as illustrated here.
DOI: 10.1002/ccr3.2394
PubMed: 31788249
PubMed Central: PMC6878056
Links to Exploration step
pubmed:31788249Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.</title><author><name sortKey="Strik, Anne S" sort="Strik, Anne S" uniqKey="Strik A" first="Anne S" last="Strik">Anne S. Strik</name><affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="D Haens, Geert R" sort="D Haens, Geert R" uniqKey="D Haens G" first="Geert R" last="D'Haens">Geert R. D'Haens</name><affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lowenberg, Mark" sort="Lowenberg, Mark" uniqKey="Lowenberg M" first="Mark" last="Löwenberg">Mark Löwenberg</name><affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31788249</idno><idno type="pmid">31788249</idno><idno type="doi">10.1002/ccr3.2394</idno><idno type="pmc">PMC6878056</idno><idno type="wicri:Area/Main/Corpus">000331</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000331</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.</title><author><name sortKey="Strik, Anne S" sort="Strik, Anne S" uniqKey="Strik A" first="Anne S" last="Strik">Anne S. Strik</name><affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="D Haens, Geert R" sort="D Haens, Geert R" uniqKey="D Haens G" first="Geert R" last="D'Haens">Geert R. D'Haens</name><affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lowenberg, Mark" sort="Lowenberg, Mark" uniqKey="Lowenberg M" first="Mark" last="Löwenberg">Mark Löwenberg</name><affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical case reports</title><idno type="ISSN">2050-0904</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Available data on switching from originator infliximab to CT-P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side effects might occur, as illustrated here.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31788249</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2050-0904</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical case reports</Title><ISOAbbreviation>Clin Case Rep</ISOAbbreviation></Journal><ArticleTitle>Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.</ArticleTitle><Pagination><MedlinePgn>2049-2053</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccr3.2394</ELocationID><Abstract><AbstractText>Available data on switching from originator infliximab to CT-P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side effects might occur, as illustrated here.</AbstractText><CopyrightInformation>© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strik</LastName><ForeName>Anne S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8879-4359</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Haens</LastName><ForeName>Geert R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Löwenberg</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Case Rep</MedlineTA><NlmUniqueID>101620385</NlmUniqueID><ISSNLinking>2050-0904</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gastroenterology and hepatology</Keyword><Keyword MajorTopicYN="N">hematology</Keyword><Keyword MajorTopicYN="N">pharmacology</Keyword><Keyword MajorTopicYN="N">toxicology</Keyword></KeywordList><CoiStatement>Anne Strik: no conflicts of interest. Mark Löwenberg: has received speaking fees from Abbvie, Covidien, Dr Falk, Ferring Pharmaceuticals, Merck Sharp & Dohme, Receptos, Takesa, Tillotts, and Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Achmea healthcare and ZonMW. Geert D’Haens: has served as advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, DrFALK Pharma, Engene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Pfizer, Prometheus laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor and received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp & Dohme, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts, and Vifor.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>07</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31788249</ArticleId><ArticleId IdType="doi">10.1002/ccr3.2394</ArticleId><ArticleId IdType="pii">CCR32394</ArticleId><ArticleId IdType="pmc">PMC6878056</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Crohns Colitis. 2016 Nov;10(11):1287-1293</Citation><ArticleIdList><ArticleId IdType="pubmed">27095751</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crohns Colitis. 2017 Jun 1;11(6):690-696</Citation><ArticleIdList><ArticleId IdType="pubmed">28130330</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 2015 Apr;60(4):951-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25326115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2013 Oct;72(10):1605-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23687259</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2015;15(9):1257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">26134250</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1290-1295</Citation><ArticleIdList><ArticleId IdType="pubmed">28902041</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crohns Colitis. 2016 Feb;10(2):133-40</Citation><ArticleIdList><ArticleId IdType="pubmed">26661272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2003 Jul;125(1):32-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12851868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2017 Jun 10;389(10086):2304-2316</Citation><ArticleIdList><ArticleId IdType="pubmed">28502609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crohns Colitis. 2016 Feb;10(2):127-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26721942</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412</Citation><ArticleIdList><ArticleId IdType="pubmed">29606564</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2013 Oct;72(10):1613-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23687260</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Gastroenterol. 2017 Dec;52(12):1348-1353</Citation><ArticleIdList><ArticleId IdType="pubmed">28838273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000331 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000331 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:31788249
|texte= Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:31788249" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |